

Essential Pharmaceuticals Asset Sale to Accord Healthcare

Torreya Advised Essential on Sale

Ewing, NJ and Durham, NC, August 8, 2017

Essential Pharmaceuticals, LLC, manufacturer and distributor of organ-preservation solution Custodiol® HTK, has been acquired by Accord Healthcare, the Durham, NC-based division of the global pharmaceutical company Intas Group, based in Ahmedabad, India. Under the terms of the agreement, Accord has acquired the rights to sell Essential's Custodiol® HTK Solution in the United States and Canada.

The transaction brings together Accord's established distribution network and Essential's expertise in organ-preservation research and development and customer service, facilitating the development and marketing of future life-saving organ-transfer medicines.

Torreya acted as exclusive financial advisor to Essential Pharmaceuticals, LLC on the asset sale. The transaction is the 19th assignment on which Torreya has advised this year and the 40th sale on which Torreya has advised in the past 18 months.

ABOUT ESSENTIAL PHARMACEUTICALS, LLC

For more information about Essential Pharmaceuticals, LLC, please see:

www.essentialpharma.com

ABOUT ACCORD HEALTHCARE

For more information about Accord Healthcare, please see:

www.accordhealthcare.us

Deal Press Release

Torreya Contact

ALLEN LEFKOWITZ

Managing Director | New York Office

allen.lefkowitz@torreya.com | 212.257.5823 | torreya.com



Asset Sale to



July 2017

Torreya is a global advisory firm serving the life sciences industry. Please visit www.torreya.com for more information. Securities offered in the United States are offered through Financial West Group, Member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 119 The Hub, 300 Kensal Road, London W10 5BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.